These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 7552519)

  • 1. Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS.
    Fleming TR; Neaton JD; Goldman A; DeMets DL; Launer C; Korvick J; Abrams D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S9-18. PubMed ID: 7552519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection.
    Goldman AI; Carlin BP; Crane LR; Launer C; Korvick JA; Deyton L; Abrams DI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):161-9. PubMed ID: 8556398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Researchers are rethinking role of AZT in drug therapy.
    AIDS Policy Law; 1995 Oct; 10(18):11. PubMed ID: 11362821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3.
    Kazempour K; Kammerman LA; Farr SS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S97-106. PubMed ID: 7552521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CPCRA 007: preliminary results of combination antiretroviral study.
    Randall P
    NIAID AIDS Agenda; 1996 Mar; ():2. PubMed ID: 11363796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3TC: combination trial stopped early as clinical benefit shown.
    James JS
    AIDS Treat News; 1996 Aug; (no 252):5. PubMed ID: 11363752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on clinical trials of combination therapies for HIV infection.
    NIAID AIDS Agenda; 1995 Sep; ():8. PubMed ID: 11362803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
    N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New trials reach same conclusion: two drugs are better than AZT alone.
    AIDS Alert; 1995 Nov; 10(11):133-6. PubMed ID: 11362921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
    Abrams DI; Goldman AI; Launer C; Korvick JA; Neaton JD; Crane LR; Grodesky M; Wakefield S; Muth K; Kornegay S
    N Engl J Med; 1994 Mar; 330(10):657-62. PubMed ID: 7906384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy increases survival.
    Treat Rev; 1995 Nov; (no 20):2-3. PubMed ID: 11363019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACTG 175 and Delta.
    Torres G
    GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZT studies reinforce benefits of combination.
    AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral drug resistance.
    Japour AJ
    AIDS Clin Care; 1995 Aug; 7(8):63-5, 67. PubMed ID: 11362787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Closing the circle on HIV--or not.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1995 Oct; 1(9):10-4, 17-29 contd. PubMed ID: 11362964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current HIV clinical trial design issues.
    Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S47-51. PubMed ID: 8595508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of late-state HIV infection.
    Millard PS
    J Fam Pract; 1997 Feb; 44(2):132-4. PubMed ID: 9040512
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.